NIEHS researchers theorize that changes in the surface proteins of cells called receptors may predispose people to diseases, such as heart disease, arthritis, and diabetes. This study needs volunteers to undergo tests to determine how these changes or variants lead to illness.
Enrolling by invitation only.
This study will require an initial screening visit and second study visit. The second visit must be completed within 14 days of the screening visit. During the first visit, we will review your medical and medication history, collect vital signs, and draw a blood sample. Additionally, a urine pregnancy test is performed for all women. You will be given a low dose of a tablet of dexamethasone to take at night before your second visit. Dexamethasone is a medicine that changes the levels of the stress hormone cortisol in the blood. This low dose test can tell how much cortisol your body is producing in response to the dexamethasone. Participants will return for a second visit for a blood draw. You will also need to fast for 12 hours overnight before both visits.
The study is run by physicians at the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, U.S. Department of Health and Human Services.
Stavros Garantziotis, M.D. is passionate about finding cures for chronic lung disease like asthma, COPD and pulmonary fibrosis. He believes that if we can understand the mechanism of disease development for every individual patient, we can design intelligent and effective treatment with less side effects. Dr. Garantziotis obtained his medical degree at the Albert-Ludwigs-University in Germany. He trained in Internal Medicine at the Albert Einstein College of Medicine in New York and in Pulmonary and Critical Care Medicine at Duke University Medical Center, where he was a faculty member before joining the NIEHS to direct the Clinical Research Unit.